RFB4-SMPT-dgA

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRFB4-SMPT-dgA
Drug Alias NameAnti-CD22 monoclonal antibody RFB4-ricin chain A conjugateRFB4-SMPT-dgAIgG-RFB4-SMPT-dgANSC639179
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionCD22 modulatorsProtein biosynthesis inhibitors
TargetsCD22
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer InstituteUniversity of Texas Southwestern Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity of Texas Southwestern Medical CenterNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A